Interaction of biomedical nanoparticles with the pulmonary immune system

Area of Science:

• Pulmonary drug delivery
• Nanomedicine
• Immunomodulation

Background:

• Engineered nanoparticles (NPs) possess unique properties for targeted delivery and immune response modulation.
• The respiratory tract is a promising site for pulmonary NP administration to interact with antigen-presenting cells (APCs).
• APCs in different lung compartments exhibit varied characteristics, making them ideal targets for inhaled immunomodulators.

Purpose of the Study:

• To review in vivo data on engineered nanoparticles for pulmonary immune modulation.
• To guide the design of nanocarrier-based strategies for respiratory disorders.
• To highlight the need for safe-by-design principles in NP development.

Main Methods:

• Focus on in vivo studies of inhalable NPs.
• Analysis of NP interactions with pulmonary APCs.
• Review of immunomodulatory potential, pharmacology, and biocompatibility.

Main Results:

• Inhalable NPs can interact with APCs in various lung compartments.
• NP properties can be tailored to modulate immune responses at different stages.
• The plasticity of APCs offers opportunities for targeted immunomodulation.

Conclusions:

• Engineered nanoparticles hold potential for treating respiratory diseases like allergic asthma.
• Further interdisciplinary research is crucial for safe and effective nanomedicine development.
• In vivo data is essential for designing successful nanocarrier-based pulmonary therapies.